Design, Structure-Activity, Labelling and Purity in the Development of Receptor Interacting Radiohalogenated Tracers

  • John Mertens
  • Henri Moereels
  • Mireille Gysemans
  • Dirk Terriere
  • Maggi Thomas
  • Josée Leysen

Abstract

The design and development of new radiohalogenated tracers for in vivo measurement of brain receptor related processes is due, to its complexity, the work of pharmaceutical companies or large multidisciplinary research groups. For the development of radiopharmaceuticals generally a compound is chosen based on its known pharmacological properties and a strategy must be developed to introduce the radioisotope.

Keywords

Radioactive Decay Iodine Atom Label Tracer Minute Post Injection Receptor Tracer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. Mertens, and M. Gysemans, CuI+ assisted nucleophilic exchange radiohalogenation: application and mechanistic approach, in: New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and regulatory Control, A.M. Emran, Plenum Press, New York and London (1991).Google Scholar
  2. 2.
    I. Nakatsuka, H. Saji, K. Shiba, H. Shimizu, M. Okuno, A. Yoshitake, and A. Yokoyama, In vitro evaluation of radioiodinated butyrophenones as radiotracer for dopamine receptor study, Life Sci, 41:1989–1997 (1987).PubMedCrossRefGoogle Scholar
  3. 3.
    J.E. Leysen, W. Gommeren, J. Mertens, W.H.M.L. Luyten, P.J. Pauwels, M. Ewert, and P. Seeburg, Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I]-2′-iodospiperone, Psychopharmac., 110:27–36 (1993).CrossRefGoogle Scholar
  4. 4.
    J. Mertens, C. Piron, F. De Geeter, L. Christieans, R. Cantineau, M. Guillaume, and J. Leysen, Evaluation of pure 2′-125I-spiperone as a promising tracer for in vivo D2 receptor study with SPECT, J. NucL Med., 30:926 (1990).Google Scholar
  5. 5.
    J. Mertens, “Clustered lipophilic compensation” a new concept in the development of lipophilic radioiodinated and brominated receptor tracers, J. Lab. Comp. Ratiopharm., 30:363 (1991).Google Scholar
  6. 6.
    J.C. Baron, Y. Samson, D. Comar, C. Crouzel, P. Deniker, Y. Agid, Etude in vivo des récepteurs serotoninergiques centraux chez l’homme par tomographic à émission de positrons, Rev. Neurol., 141:537–545 (1985).PubMedGoogle Scholar
  7. 7.
    C. Lemaire, R. Cantineau, M. Guillaume, A. Plenevaux, L. Christiaens, Fluorine-18-Altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats, J. Nucl. Med., 32:2266–2272 (1991).PubMedGoogle Scholar
  8. 8.
    H. D’haenen, A. Bossuyt, J. Mertens, C. Bossuyt-Piron, M. Gysemans, and L. Kaufman, SPECT imaging of serotonin2 receptors in depression, Psychiat. Res: Neuroimaging., 45:227–237 (1992).CrossRefGoogle Scholar
  9. 9.
    M.R. Kilbourn, and M.R. Zalutsky, Research and clinical potential of receptor based radiopharmaceuticals, J. NucL Med., 26:655–662 (1985).PubMedGoogle Scholar
  10. 10.
    J. Mertens, M. Gysemans, C. Piron, M. Thomas, High yield preparation of pure 2-radioiodo-ketanserin of high specific acitivity, a serotonin S2 receptor tracer for SPECT, J. Lab. Comp. Ratiopharm., 28:731–738 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • John Mertens
    • 1
  • Henri Moereels
    • 2
  • Mireille Gysemans
    • 1
  • Dirk Terriere
    • 1
  • Maggi Thomas
    • 1
  • Josée Leysen
    • 2
  1. 1.VUB-CyclotronVrije Universiteit BrusselBrusselsBelgium
  2. 2.Janssen Research FoundationBeerseBelgium

Personalised recommendations